Benjamin Neale

Associate Professor

Broad Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

There is still relatively little known about the genetic underpinnings of proteomic aging clocks. Here, we describe a genome-wide association study of proteomic aging in the UK Biobank (n=38,865), identifying 27 loci associated with participants’ proteomic age gap (ProtAgeGap). ProtAgeGap exhibits a strong genetic correlation with longevity (rg = −0.83), and in FinnGen a ProtAgeGap polygenic score (PGS) was associated with significantly increased odds of achieving longevity (n=500,348; OR = 1.43). Additional PGS analyses in All of Us (n=117,415), China Kadoorie Biobank (n=100,640), and ABCD Study (n=5,204) demonstrate reproducible associations across biobanks of ProtAgeGap PGS with obesity, cardiometabolic disease, and osteoarthritis in adults, and with developmental timing in children. Finally, colocalization analysis identified FTO as an obesity-related mechanism uniting diverse aging traits. Our results demonstrate a shared genetic architecture across the life course of ProtAgeGap with longevity, early developmental biology, and cardiometabolic and musculoskeletal diseases.

Year:

2025

One of the strongest signatures of aging is an accumulation of mutant mitochondrial DNA (mtDNA) heteroplasmy. Here we investigate the mechanism underlying this phenomenon by calling mtDNA sequence, abundance, and heteroplasmic variation in human blood using whole genome sequences from ∼750,000 individuals. Our analyses reveal a simple, two-step mechanism: first, individual cells randomly accumulate low levels of “cryptic” mtDNA mutations; then, when a cell clone proliferates, the cryptic mtDNA variants are carried as passenger mutations and become detectable in whole blood. Four lines of evidence support this model: (1) the mutational spectrum of age-accumulating mtDNA variants is consistent with a well-established model of mtDNA replication errors, (2) these mutations are found primarily at low levels of heteroplasmy and do not show evidence of positive selection, (3) high mtDNA mutation burden tends to co-occur in samples harboring somatic driver mutations for clonal hematopoiesis (CH), and (4) nuclear GWAS reveals that germline variants predisposing to CH (such as those near TERT , TCL1A , and SMC4 ) also increase mtDNA mutation burden. We propose that the high copy number and high mutation rate of mtDNA make it a particularly sensitive blood-based marker of CH. Importantly, our work helps to mechanistically unify three prominent signatures of aging: common germline variants in TERT , clonal hematopoiesis, and observed mtDNA mutation accrual.

Year:

2025

Key Points Question Is variation in global functioning among people with schizophrenia associated with genetic differences? Findings In this genetic association study of 5991 adults with schizophrenia and 59,795 hospitalizations, polygenic scores for schizophrenia and educational attainment predicted global functioning at psychiatric admission and discharge, as well as the magnitude of functional improvement during hospitalization. Higher polygenic burden for schizophrenia was consistently associated with worse functional outcomes, including less functional improvement during hospitalization, while educational attainment polygenic score showed a more complex pattern of associations. Meaning Polygenic scores may help disentangle heterogeneity in schizophrenia functioning and course. Importance Schizophrenia is characterized by heterogeneity in disease outcomes and course. The extent to which this heterogeneity is associated with genetic variation is unclear. Objective To investigate whether polygenic scores (PGS) for schizophrenia and educational attainment are associated with global functioning during inpatient psychiatric hospitalization among patients with schizophrenia. Design, Setting, and Participants Adults with schizophrenia were recruited nationwide for the SUPER-Finland Study between 2015 and 2018. Global functioning scores recorded during hospitalizations between 1994 and 2019 were extracted from a complete, longitudinal register. Data for the current genetic association study were analyzed between May 2024 and April 2025. We used linear mixed-effects models to examine associations among PGS and global functioning at admission and discharge, as well as functional change during hospitalization. Exposures Psychiatric hospitalization and PGS for schizophrenia and educational attainment. Main Outcomes and Measures Admission global functioning, discharge global functioning, and functional change during hospitalization. Results We analyzed 117,810 global functioning scores from 59,795 hospitalizations and 5991 participants (2733 [45.62%] female, median [IQR] age = 47 [20] years). Higher schizophrenia PGS predicted lower admission global functioning ( β = −0.20; 95% CI, −0.40 to 0.00; P = .05) and discharge global functioning ( β = −0.36; 95% CI,−0.56 to −0.17; P < .001), and less functional improvement ( β = −0.31; 95% CI, −0.49 to −0.14; P < .001). Higher educational attainment PGS predicted greater functional improvement ( β = 0.20; 95% CI, 0.03 to 0.37; P = .02) but worse admission global functioning ( β = −0.23; 95% CI, −0.43 to −0.04; P = .02). Conclusions and Relevance Higher genetic liability for schizophrenia is associated with worse global functioning across psychiatric hospitalization, including less functional improvement. Integrating PGS and clinically relevant, longitudinal disease outcomes may help parse heterogeneity in schizophrenia prognosis and course.

Year:

2025

Thyroid diseases are common and highly heritable. Under the Global Biobank Meta-analysis Initiative, we performed a meta-analysis of genome-wide association studies from 19 biobanks for five thyroid diseases: thyroid cancer, benign nodular goiter, Graves’ disease, lymphocytic thyroiditis, and primary hypothyroidism. We analyzed genetic association data from ∼2.9 million genomes and identified 235 known and 501 novel independent variants significantly linked to thyroid diseases. We discovered genetic correlations between thyroid cancer, benign nodular goiter, and autoimmune thyroid diseases ( r 2 =0.21-0.97). Telomere maintenance genes contribute to benign and malignant thyroid nodular disease risk, whereas cell cycle, DNA repair, and DNA damage response genes are predominantly associated with thyroid cancer. We proposed a paradigm explaining genetic predisposition to benign and malignant thyroid nodules. We evaluated thyroid cancer polygenic risk scores (PRS) for clinical applications in thyroid cancer diagnosis. We found PRS associations with thyroid cancer risk features: multifocality, lymph node metastases, and extranodal extension.

Year:

2025

Psychiatric disorders display high levels of comorbidity and genetic overlap 1,2 . Genomic methods have shown that even for schizophrenia and bipolar disorder, two disorders long-thought to be etiologically distinct 3 , the majority of genetic signal is shared 4 . Furthermore, recent cross-disorder analyses have uncovered over a hundred pleiotropic loci shared across eight disorders 5 . However, the full scope of shared and disorder-specific genetic basis of psychopathology remains largely uncharted. Here, we address this gap by triangulating across a suite of cutting-edge statistical genetic and functional genomic analyses applied to 14 childhood- and adult-onset psychiatric disorders (1,056,201 cases). Our analyses identify and characterize five underlying genomic factors 6 that explain the majority of the genetic variance of the individual disorders (∼66% on average) and are associated with 268 pleiotropic loci. We observed particularly high levels of polygenic overlap 7 and local genetic correlation 8 and very few disorder-specific loci 9 for two factors defined by: ( i ) schizophrenia and bipolar disorder (“SB factor”), and by ( ii ) major depression, PTSD, and anxiety (“internalizing factor”). At the functional level, we applied multiple methods 10–12 which demonstrated that the shared genetic signal across the SB factor was substantially enriched in genes expressed in excitatory neurons, whereas the internalizing factor was associated with oligodendrocyte biology. By comparison, the genetic signal shared across all 14 disorders was enriched for broad biological processes (e.g., transcriptional regulation). These results indicate increasing differentiation of biological function at different levels of shared cross-disorder risk, from quite general vulnerability to more specific pathways associated with subsets of disorders. These observations may inform a more neurobiologically valid psychiatric nosology and implicate novel targets for therapeutic developments designed to treat commonly occurring comorbid presentations.

Year:

2025

Motivation The Variant Call Format (VCF) is widely used in genome sequencing but scales poorly. For instance, we estimate a 150 000 genome VCF would occupy 900 TiB, making it costly and complicated to produce, analyze, and store. The issue stems from VCF’s requirement to densely represent both reference-genotypes and allele-indexed arrays. These requirements lead to unnecessary data duplication and, ultimately, very large files. Results To address these challenges, we introduce the Scalable Variant Call Representation (SVCR). This representation reduces file sizes by ensuring they scale linearly with samples. SVCR’s linear scaling relies on two techniques, both necessary for linearity: local allele indices and reference blocks, which were first introduced by the Genomic Variant Call Format. SVCR is also lossless and mergeable, allowing for N + 1 and N + K incremental joint-calling. We present two implementations of SVCR: SVCR-VCF, which encodes SVCR in VCF format, and VDS, which uses Hail’s native format. Our experiments confirm the linear scalability of SVCR-VCF and VDS, in contrast to the super-linear growth seen with standard VCF files. We also discuss the VDS Combiner, a scalable, open-source tool for producing a VDS from GVCFs and unique features of VDS which enable rapid data analysis. SVCR, and VDS in particular, ensure the scientific community can generate, analyze, and disseminate genetics datasets with millions of samples. Availability and implementation https://github.com/hail-is/hail/.

Year:

2024

Background The Populations Underrepresented in Mental illness Association Studies (PUMAS) project is attempting to remediate the historical underrepresentation of African and Latin American populations in psychiatric genetics through large-scale genetic association studies of individuals diagnosed with a serious mental illness [SMI, including schizophrenia (SCZ), schizoaffective disorder (SZA) bipolar disorder (BP), and severe major depressive disorder (MDD)] and matched controls. Given growing evidence indicating substantial symptomatic and genetic overlap between these diagnoses, we sought to enable transdiagnostic genetic analyses of PUMAS data by conducting phenotype alignment and harmonization for 89,320 participants (48,165 cases and 41,155 controls) from four cohorts, each of which used different ascertainment and assessment methods: PAISA n=9,105; PUMAS-LATAM n=14,638; NGAP n=42,953 and GPC n=22,624. As we describe here, these efforts have yielded harmonized datasets enabling us to analyze PUMAS genetic variation data at three levels: SMI overall, diagnoses, and individual symptoms. Methods In aligning item-level phenotypes obtained from 14 different clinical instruments, we incorporated content, branching nature, and time frame for each phenotype; standardized diagnoses; and selected 19 core SMI item-level phenotypes for analyses. The harmonization was evaluated in PUMAS cases using multiple correspondence analysis (MCA), co-occurrence analyses, and item-level endorsement. Outcomes We mapped >6,895 item-level phenotypes in the aggregated PUMAS data, in which SCZ (44.97%) and severe BP (BP-I, 31.53%) were the most common diagnoses. Twelve of the 19 core item-level phenotypes occurred at frequencies of > 10% across all diagnoses, indicating their potential utility for transdiagnostic genetic analyses. MCA of the 14 phenotypes that were present for all cohorts revealed consistency across cohorts, and placed MDD and SCZ into separate clusters, while other diagnoses showed no significant phenotypic clustering. Interpretation Our alignment strategy effectively aggregated extensive phenotypic data obtained using diverse assessment tools. The MCA yielded dimensional scores which we will use for genetic analyses along with the item level phenotypes. After successful harmonization, residual phenotypic heterogeneity between cohorts reflects differences in branching structure of diagnostic instruments, recruitment strategies, and symptom interpretation (due to cultural variation).

Year:

2024

Genome-wide association studies (GWAS) and rare-variant association studies (RVAS) have identified thousands of genes and variants associated with diverse human phenotypes, and have revealed pervasive pleiotropy among common variants; however, the extent of pleiotropy among rare variants remains incompletely characterized. Using rare variant association results from the UK Biobank (UKB), we systematically quantify gene-level pleiotropy across hundreds of phenotypes spanning multiple phenotypic domains and identify genes exhibiting allelic series. We develop ALLSPICE (ALLelic Spectrum of Pleiotropy Informed Correlated Effects), a statistical test for assessing variant effect heterogeneity within pleiotropic genes across quantitative traits. In ALB , a gene associated with both albumin and calcium levels, ALLSPICE reveals a subset of missense variants with heterogeneous effects across these traits. Protein structure-based analyses further demonstrate that missense variants associated with calcium levels but not albumin, as well as variants with opposing effects on the two traits, are enriched near known calcium-binding sites in the ALB protein. In this way, we present a systematic view of gene-level pleiotropy and effect heterogeneity among rare variants, illustrating how shared and trait-specific genetic effects can arise within the same gene. Our analysis provides a general approach for dissecting pleiotropic architecture and detecting rare variants with heterogeneous effects for downstream biological investigation of complex human traits.

Year:

2024

Motivation Functional Annotation of genomic Variants Online Resources (FAVOR) offers multi-faceted, whole genome variant functional annotations, which is essential for Whole Genome and Exome Sequencing (WGS/WES) analysis and the functional prioritization of disease-associated variants. A versatile chatbot designed to facilitate informative interpretation and interactive, user-centric summary of the whole genome variant functional annotation data in the FAVOR database is needed. Results We have developed FAVOR-GPT, a generative natural language interface powered by integrating large language models (LLMs) and FAVOR. It is developed based on the Retrieval Augmented Generation (RAG) approach, and complements the original FAVOR portal, enhancing usability for users, especially those without specialized expertise. FAVOR-GPT simplifies raw annotations by providing interpretable explanations and result summaries in response to the user’s prompt. It shows high accuracy when cross-referencing with the FAVOR database, underscoring the robustness of the retrieval framework. Availability and implementation Researchers can access FAVOR-GPT at FAVOR’s main website (https://favor.genohub.org).

Year:

2024

We deployed the Blended Genome Exome (BGE), a DNA library blending approach that generates low pass whole genome (1-4x mean depth) and deep whole exome (30-40x mean depth) data in a single sequencing run. This technology is cost-effective, empowers most genomic discoveries possible with deep whole genome sequencing, and provides an unbiased method to capture the diversity of common SNP variation across the globe. To evaluate this new technology at scale, we applied BGE to sequence >53,000 samples from the Populations Underrepresented in Mental Illness Associations Studies (PUMAS) Project, which included participants across African, African American, and Latin American populations. We evaluated the accuracy of BGE imputed genotypes against raw genotype calls from the Illumina Global Screening Array. All PUMAS cohorts had R 2 concordance ≥95% among SNPs with MAF≥1%, and never fell below ≥90% R 2 for SNPs with MAF<1%. Furthermore, concordance rates among local ancestries within two recently admixed cohorts were consistent among SNPs with MAF≥1%, with only minor deviations in SNPs with MAF<1%. We also benchmarked the discovery capacity of BGE to access protein-coding copy number variants (CNVs) against deep whole genome data, finding that deletions and duplications spanning at least 3 exons had a positive predicted value of ∼90%. Our results demonstrate BGE scalability and efficacy in capturing SNPs, indels, and CNVs in the human genome at 28% of the cost of deep whole-genome sequencing. BGE is poised to enhance access to genomic testing and empower genomic discoveries, particularly in underrepresented populations.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (77)

Jordan Smoller

Professor

Massachusetts General Hospital

UNITED STATES
View details

M. Austin Argentieri

Broad Institute

UNITED STATES
View details

Naomi Wray

University of Queensland

AUSTRALIA
View details

Vamsi Mootha

Investigator / Professor

-

UNITED STATES
View details

Elinor Karlsson

Associate Professor

University of Massachusetts Chan Medical School

UNITED STATES
View details

Serghei Mangul

University of Southern California

UNITED STATES
View details

David van Heel

Professor

Queen Mary University of London

UNITED KINGDOM
View details

Stephen V Faraone

Distinguished Professor

SUNY Upstate Medical University

UNITED STATES
View details

G. Bragi Walters

Research Assistant Professor

University of Iceland

ICELAND
View details

Howard Edenberg

Distinguished Professor

Indiana University School of Medicine

UNITED STATES
View details

Susan Santangelo

Research Professor

Tufts University School of Medicine

UNITED STATES
View details

Ditte Demontis

Aarhus University

DENMARK
View details

Robin Walters

University of Oxford

UNITED KINGDOM
View details

Na Cai

Assistant Professor

ETH Zürich

SWITZERLAND
View details

Alicia Martin

Assistant Professor

Massachusetts General Hospital

UNITED STATES
View details

Michele Pato

Associate Dean for Academic Scholarship; Associate Chair for Education and Faculty Development; Della Martin Chair, Professor of Psychiatry; Clinical Director of Center for Genomic Psychiatry

Rutgers University

UNITED STATES
View details

Bjørn Olav Åsvold

-

NORWAY
View details

Joseph Powell

University of New South Wales

AUSTRALIA
View details

Roel A. Ophoff

Professor

University of California, Los Angeles

UNITED STATES
View details

Shawneequa Callier

Associate Professor

George Washington University

UNITED STATES
View details

Charles Newton

University of Oxford

UNITED KINGDOM
View details

Caroline Nievergelt

Professor

University of California, San Diego

UNITED STATES
View details

James Knowles

Distinguished Professor and Executive Director of the HGINJ

Rutgers University - Busch Campus

UNITED STATES
View details

Joanna Biernacka

Associate Professor

Mayo Clinic

UNITED STATES
View details

Andrew Grotzinger

Associate Professor

Memorial University of Newfoundland

CANADA
View details

Lori Chibnik

Massachusetts General Hospital

UNITED STATES
View details

Bizu Gelaye

Chief, Epidemiology Branch and Senior Investigator

Eunice Kennedy Shriver National Institute of Child Health and Human Development

UNITED STATES
View details

Kenneth S. Kendler

Professor

Virginia Commonwealth University

UNITED STATES
View details

Pradeep Natarajan

Associate Professor

Harvard Medical School

UNITED STATES
View details

John Hettema

Professor

Texas A&M University

UNITED STATES
View details

Phil Lee

Associate Professor

Massachusetts General Hospital

UNITED STATES
View details

Oleksandr Frei

Associate Professor (20%)

University of Oslo

NORWAY
View details

Tim B. Bigdeli

SUNY Downstate Health Sciences University

UNITED STATES
View details

Sandra Sanchez-Roige

Associate Professor

University of California, San Diego

UNITED STATES
View details

Neil Wright

University of Oxford

UNITED KINGDOM
View details

Baihan Wang

University of Oxford

UNITED KINGDOM
View details

Toni Boltz

Massachusetts General Hospital

UNITED STATES
View details

Evan Koch

Assistant Professor

Yale University

UNITED STATES
View details

Aarno Palotie

University of Helsinki

FINLAND
View details

Murray Stein

Distinguished Professor

University of California, San Diego

UNITED STATES
View details

Canqing Yu

Associate Professor

Peking University

CHINA
View details

Derrick Bennett

Professor

University of Oxford

UNITED KINGDOM
View details

Zhiping Weng

Department Chair/Professor

University of Massachusetts Chan Medical School

UNITED STATES
View details

Laura Thornton

Research Professor

University of North Carolina

UNITED STATES
View details

Kari Stefansson

Professor

University of Iceland

ICELAND
View details

Sarah Medland

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Luke O'Connor

Assistant Professor

Harvard Medical School

UNITED STATES
View details

David Whiteman

Deputy Director

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Elizabeth Atkinson

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Najaf Amin

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Joel Gelernter

Professor

Yale University School of Medicine

UNITED STATES
View details

Markku Lähteenvuo

Niuvanniemi Hospital

FINLAND
View details

Simone Rubinacci

FIMM/EMBL Group Leader in Statistical Genomics

University of Helsinki

FINLAND
View details

Predrag Radivojac

Northeastern University

UNITED STATES
View details

Zhengming Chen

Professor of Epidemeology, Director of China Programme

University of Oxford

UNITED KINGDOM
View details

Manuel Mattheisen

Associate Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Barbara Franke

Head of department

Radboud University Medical Center

NETHERLANDS
View details

Michael Gandal

William & Noreen Hetznecker Associate Professor

University of Pennsylvania

UNITED STATES
View details

Evan Giangrande

Assistant Professor

University of South Carolina

UNITED STATES
View details

Josefin Werme

University of Amsterdam

NETHERLANDS
View details

Olli Pietilainen

Group Leader

University of Helsinki

FINLAND
View details

Michael Talkowski

Professor

Massachusetts General Hospital

UNITED STATES
View details

Karen Mitchell

Assistant Professor

Boston University

UNITED STATES
View details

Shamil Sunyaev

Professor

Harvard University

UNITED STATES
View details

Elliot M. Tucker-Drob

Faculty Research Associate

University of Texas at Austin

UNITED STATES
View details

Dan Stein

Professor and Chair of Psychiatry

University of Cape Town

SOUTH AFRICA
View details

Ole A. Andreassen

Oslo University Hospital

NORWAY
View details

Kai Yuan

Assistant Professor

Indiana University School of Medicine

UNITED STATES
View details

Irwin Waldman

Professor

Emory University

UNITED STATES
View details

Brandon Coombes

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Wouter Peyrot

VU medisch centrum

NETHERLANDS
View details

Katherine Jonas

Assistant Professor

Stony Brook University

UNITED STATES
View details

Cornelia Van Duijn

Professor

University of Oxford

UNITED KINGDOM
View details

Xihong Lin

Professor

Harvard University

UNITED STATES
View details

Anne O'Donnell-Luria

Associate Professor

Boston Children's Hospital

UNITED STATES
View details

Jaana Suvisaari

Research Professor

National Institute for Health and Welfare

FINLAND
View details

John Nurnberger

Professor/Distinguished Professor

Indiana University School of Medicine

UNITED STATES
View details